Treatment with Indapamide in Patients with Post-Surgical Hypoparathyroidism

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516000-41-01

Enrollment

Registered

2025-02-26

Start date

2025-06-04

Completion date

Unknown

Last updated

2025-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoparathyroidism

Brief summary

Changes in 24-hour urinary calcium excretion after 14 days of treatment, Changes in 24-hour urinary calcium excretion after 7 days of treatment

Detailed description

Changes in plasma ionized calcium after 7 and 14 days of treatment, Changes in supplementation with active vitamin D and oral calcium after 7 and 14 days of treatment, Changes in plasma ionized calcium in the placebo period due to a sodium restrictive diet, Changes in 24-hour urinary calcium excretion in the placebo period due to a sodium restrictive diet

Interventions

DRUGINDAPAMIDE

DRUGPlacebo tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Changes in 24-hour urinary calcium excretion after 14 days of treatment, Changes in 24-hour urinary calcium excretion after 7 days of treatment	—

Secondary

Measure	Time frame
Changes in plasma ionized calcium after 7 and 14 days of treatment, Changes in supplementation with active vitamin D and oral calcium after 7 and 14 days of treatment, Changes in plasma ionized calcium in the placebo period due to a sodium restrictive diet, Changes in 24-hour urinary calcium excretion in the placebo period due to a sodium restrictive diet	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026